Science and Research
COAST: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
A study of OPT-302 with aflibercept in neovascular age-related macular degeneration (nAMD) (COAST).
Overview
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Clinical Trials Research Centre on (03) 99298076 or email trials@cera.org.au.
- Principal Investigator
Dr Thanh Nguyen
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Clinical Trials Research Centre on (03) 99298076 or email trials@cera.org.au.
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.